Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma

Nozato,Megumi; Kaneko,Setsuko; Nakagawara,Akira; Komuro,Hiroaki

doi:10.3892/ijo.2012.1684

Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma

Authors:
- Megumi Nozato
- Setsuko Kaneko
- Akira Nakagawara
- Hiroaki Komuro
View Affiliations

Affiliations: Department of Pediatric Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, Chiba Cancer Center Research Institute, Chiba, Japan, Department of Pediatric Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Published online on: November 6, 2012 https://doi.org/10.3892/ijo.2012.1684
Pages: 134-140
Copyright: © Nozato et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroblastoma (NB) is a highly metastatic tumor in children. The epithelial-mesenchymal transition (EMT) is an important mechanism for both the initiation of tumor invasion and subsequent metastasis. This study investigated the role of EMT in the progression of NB. Using EMT assays on samples from 11 tumors, we identified 14 genes that were either differentially expressed between tumors of different stages or highly upregulated in NB. Quantitative RT‑PCR of these genes was conducted in 96 NB tumors and their expression levels were compared between stages and between tumors with the presence and absence of MYCN amplification. The association of survival rate with differential gene expression was investigated. Expression of KRT19 was significantly decreased in stage 3 or 4 NB as well as stage 4S NB compared with stage 1 or 2 NB. Expression levels of KRT19 and ERBB3 were significantly low, and expression levels of TWST1 and TCF3 were high in MYCN‑amplified NB. The patients with low expression of KRT19 or ERBB3 showed significantly worse overall survival. Furthermore, the correlation between high invasive ability and low expression of KRT19 and ERBB3 was suggested in vitro using six NB cell lines. The authors conclude that downregulation of KRT19 is highly associated with tumor progression in NB and metastasis in localized primary NB and that low expression of ERBB3 is also associated with progression of NB.

View Figures

View References

1.	Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003. View Article : Google Scholar : PubMed/NCBI
2.	Maris JM: Recent advances in neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
3.	Maris JM: The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 17:7–13. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Yang J and Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
6.	Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 172:973–981. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
8.	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Moll R, Franke WW, Schiller DL, Geiger B and Krepler R: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 31:11–24. 1982. View Article : Google Scholar : PubMed/NCBI
10.	Carén H, Djos A, Nethander M, Sjöberg RM, Kogner P, Enström C, Nilsson S and Martinsson T: Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer. 11:662011.PubMed/NCBI
11.	Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117:927–939. 2004. View Article : Google Scholar : PubMed/NCBI
12.	Karreth F and Tuveson DA: Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol Ther. 3:1058–1059. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, Combaret V, Krause A, Leissner P and Puisieux A: Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell. 6:625–630. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Puisieux A, Valsesia-Wittmann S and Ansieau S: A twist for survival and cancer progression. Br J Cancer. 94:13–17. 2006. View Article : Google Scholar : PubMed/NCBI
15.	Perez-Moreno MA, Locascio A, Rodrigo I, Dhondt G, Portillo F, Nieto MA and Cano A: A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J Biol Chem. 276:27424–27431. 2001. View Article : Google Scholar : PubMed/NCBI
16.	Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE and Brodeur GM: Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res. 65:9868–9875. 2005. View Article : Google Scholar : PubMed/NCBI
17.	Tamura S, Hosoi H, Kuwahara Y, Kikuchi K, Otabe O, Izumi M, Tsuchiya K, Iehara T, Gotoh T and Sugimoto T: Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochem Biophys Res Commun. 358:226–232. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Chiu B, Mirkin B and Madonna MB: Epidermal growth factor can induce apoptosis in neuroblastoma. J Pediatr Surg. 42:482–488. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Chiu B, Mirkin B and Madonna MB: Mitogenic and apoptotic actions of epidermal growth factor on neuroblastoma cells are concentration-dependent. J Surg Res. 135:209–212. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Chiu B, Mirkin B and Madonna MB: Novel action of epidermal growth factor on caspase 3 and its potential as a chemotherapeutic adjunct for neuroblastoma. J Pediatr Surg. 42:1389–1395. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Richards KN, Zweidler-McKay PA, Van Roy N, Speleman F, Trevino J, Zage PE and Hughes DP: Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer. 116:3233–3243. 2010. View Article : Google Scholar : PubMed/NCBI
22.	Gambini C, Sementa AR, Boni L, Marino CE, Croce M, Negri F, Pistoia V, Ferrini S and Corrias MV: Expression of HER2/neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression. Cancer Immunol Immunother. 52:116–120. 2003.PubMed/NCBI
23.	Izycka-Swieszewska E, Wozniak A, Drozynska E, Kot J, Grajkowska W, Klepacka T, Perek D, Koltan S, Bien E and Limon J: Expression and significance of HER family receptors in neuroblastic tumors. Clin Exp Metastasis. 28:271–282. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Sithanandam G and Anderson LM: The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Therapy. 15:413–448. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Gullick WJ: The c-erbB3/HER3 receptor in human cancer. Cancer Surv. 27:339–349. 1996.PubMed/NCBI
26.	Travis A, Pinder SE, Robertson JF, Bell JA, Wencyk P, Gullick WJ, Nicholson RI, Poller DN, Blamey RW, Elston CW and Ellis IO: C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer. 74:229–233. 1996. View Article : Google Scholar : PubMed/NCBI
27.	Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM and Moasser MM: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 445:437–441. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Baselga J and Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 9:463–475. 2009. View Article : Google Scholar : PubMed/NCBI
29.	Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M and Tanabe KK: Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res. 68:2391–2399. 2008. View Article : Google Scholar
30.	Thomson S, Petti F, Sujka-Kwok I, Epstein D and Haley JD: Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis. 25:843–854. 2008. View Article : Google Scholar : PubMed/NCBI